Skip to main content
Erschienen in: CNS Drugs 7/2019

01.07.2019 | Review Article

Outcome Assessment in Trials of Pharmacological Treatments for Alcohol Use Disorders: Fair and Strict Testing

verfasst von: Susanne Rösner, Michael Soyka

Erschienen in: CNS Drugs | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Outcome assessment in the pharmacological treatment of alcohol use disorders (AUDs) faces specific challenges resulting from low adherence to treatment, high rates of dropout, and the susceptibility of patient self-reports to bias. This review discusses methodological issues in planning, conducting, and interpreting clinical trials on AUD treatment against the background of the principle of ‘strictness and fairness’ of testing. Threats to fairness include factors that limit the implementation of an intervention, such as low compliance and early treatment termination. In turn, fairness of testing is increased by factors that support the degree to which an intervention is implemented, such as the use of adequate pretreatments and the matching of psychosocial and pharmacological treatment strategies. Furthermore, selecting outcomes on the basis of an intervention’s mechanism of action and including continuous outcomes as sensitive measures of drinking change further increases fairness by increasing the likelihood that the data will adequately reflect the effects of the intervention. On the other hand, strictness of testing is increased by all measures that limit the influence of confounders that could potentially lead to an overestimation of effects. The use of a side effect-mimicking placebo to prevent an unmasking of blinding and the repeated assessment of alcohol biomarkers to validate drinking self-reports might be valid strategies to further increase the strictness of testing by limiting risks of bias in trials of AUD treatment.
Literatur
1.
Zurück zum Zitat Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry. 2015;72(8):757–66.CrossRef Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry. 2015;72(8):757–66.CrossRef
2.
Zurück zum Zitat Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815–24.CrossRef Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815–24.CrossRef
3.
Zurück zum Zitat Rehm J, Dawson D, Frick U, Gmel G, Roerecke M, Shield KD, et al. Burden of disease associated with alcohol use disorders in the United States. Alcohol Clin Exp Res. 2014;38(4):1068–77.CrossRef Rehm J, Dawson D, Frick U, Gmel G, Roerecke M, Shield KD, et al. Burden of disease associated with alcohol use disorders in the United States. Alcohol Clin Exp Res. 2014;38(4):1068–77.CrossRef
4.
Zurück zum Zitat Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. 2015;110(6):920–30.CrossRef Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. 2015;110(6):920–30.CrossRef
5.
Zurück zum Zitat Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275–93.CrossRef Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275–93.CrossRef
6.
Zurück zum Zitat Brorson HH, Ajo Arnevik E, Rand-Hendriksen K, Duckert F. Drop-out from addiction treatment: a systematic review of risk factors. Clin Psychol Rev. 2013;33(8):1010–24.CrossRef Brorson HH, Ajo Arnevik E, Rand-Hendriksen K, Duckert F. Drop-out from addiction treatment: a systematic review of risk factors. Clin Psychol Rev. 2013;33(8):1010–24.CrossRef
7.
Zurück zum Zitat Raes V, De Jong CA, De Bacquer D, Broekaert E, De Maeseneer J. The effect of using assessment instruments on substance-abuse outpatients’ adherence to treatment: a multi-centre randomised controlled trial. BMC Health Serv Res. 2011;11:123.CrossRef Raes V, De Jong CA, De Bacquer D, Broekaert E, De Maeseneer J. The effect of using assessment instruments on substance-abuse outpatients’ adherence to treatment: a multi-centre randomised controlled trial. BMC Health Serv Res. 2011;11:123.CrossRef
8.
Zurück zum Zitat Matthews S, Dwyer R, Snoek A. Stigma and self-stigma in addiction. J Bioeth Inq. 2017;14(2):275–86.CrossRef Matthews S, Dwyer R, Snoek A. Stigma and self-stigma in addiction. J Bioeth Inq. 2017;14(2):275–86.CrossRef
9.
Zurück zum Zitat Schomerus G, Matschinger H, Angermeyer MC. Attitudes towards alcohol dependence and affected individuals: persistence of negative stereotypes and illness beliefs between 1990 and 2011. Eur Addict Res. 2014;20(6):293–9.CrossRef Schomerus G, Matschinger H, Angermeyer MC. Attitudes towards alcohol dependence and affected individuals: persistence of negative stereotypes and illness beliefs between 1990 and 2011. Eur Addict Res. 2014;20(6):293–9.CrossRef
10.
Zurück zum Zitat Yoshino A, Kato M. Influence of social desirability response set on self-report for assessing the outcome of treated alcoholics. Alcohol Clin Exp Res. 1995;19(6):1517–9.CrossRef Yoshino A, Kato M. Influence of social desirability response set on self-report for assessing the outcome of treated alcoholics. Alcohol Clin Exp Res. 1995;19(6):1517–9.CrossRef
11.
Zurück zum Zitat Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;9:CD004332. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;9:CD004332.
12.
Zurück zum Zitat Allen JP. Measuring outcome in interventions for alcohol dependence and problem drinking: executive summary of a conference sponsored by the National Institute on alcohol abuse and alcoholism. Alcohol Clin Exp Res. 2003;27(10):1657–60.CrossRef Allen JP. Measuring outcome in interventions for alcohol dependence and problem drinking: executive summary of a conference sponsored by the National Institute on alcohol abuse and alcoholism. Alcohol Clin Exp Res. 2003;27(10):1657–60.CrossRef
13.
Zurück zum Zitat Westermann R, Hager W. Error probabilities in educational and psychological research. J Educ Stat. 1986;11:117–46.CrossRef Westermann R, Hager W. Error probabilities in educational and psychological research. J Educ Stat. 1986;11:117–46.CrossRef
14.
Zurück zum Zitat Moos RH, Moos BS. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction. 2006;101(2):212–22.CrossRef Moos RH, Moos BS. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction. 2006;101(2):212–22.CrossRef
15.
Zurück zum Zitat Witkiewitz K, Finney JW, Harris AH, Kivlahan DR, Kranzler HR. Guidelines for the reporting of treatment trials for alcohol use disorders. Alcohol Clin Exp Res. 2015;39(9):1571–81.CrossRef Witkiewitz K, Finney JW, Harris AH, Kivlahan DR, Kranzler HR. Guidelines for the reporting of treatment trials for alcohol use disorders. Alcohol Clin Exp Res. 2015;39(9):1571–81.CrossRef
16.
Zurück zum Zitat Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–900.CrossRef Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–900.CrossRef
17.
Zurück zum Zitat Shen WW. Anticraving therapy for alcohol use disorder: a clinical review. Neuropsychopharmacol Rep. 2018;38(3):105–16.CrossRef Shen WW. Anticraving therapy for alcohol use disorder: a clinical review. Neuropsychopharmacol Rep. 2018;38(3):105–16.CrossRef
18.
Zurück zum Zitat Minozzi S, Saulle R, Rosner S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2018;11:CD012557.PubMed Minozzi S, Saulle R, Rosner S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2018;11:CD012557.PubMed
19.
Zurück zum Zitat Pierce M, Sutterland A, Beraha EM, Morley K, van den Brink W. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2018;28(7):795–806.CrossRef Pierce M, Sutterland A, Beraha EM, Morley K, van den Brink W. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2018;28(7):795–806.CrossRef
20.
Zurück zum Zitat Mutschler J, Grosshans M, Soyka M, Rosner S. Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry. 2016;49(4):137–41.CrossRef Mutschler J, Grosshans M, Soyka M, Rosner S. Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry. 2016;49(4):137–41.CrossRef
21.
Zurück zum Zitat Rosner S, Grosshans M, Mutschler JH. Disulfiram: Aktuelle Befunde und Wirkmechanismen. Suchtmedizin. 2014;16(2):47–52. Rosner S, Grosshans M, Mutschler JH. Disulfiram: Aktuelle Befunde und Wirkmechanismen. Suchtmedizin. 2014;16(2):47–52.
22.
Zurück zum Zitat Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366.CrossRef Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366.CrossRef
23.
Zurück zum Zitat Bujarski S, O’Malley SS, Lunny K, Ray LA. The effects of drinking goal on treatment outcome for alcoholism. J Consult Clin Psychol. 2013;81(1):13–22.CrossRef Bujarski S, O’Malley SS, Lunny K, Ray LA. The effects of drinking goal on treatment outcome for alcoholism. J Consult Clin Psychol. 2013;81(1):13–22.CrossRef
24.
Zurück zum Zitat Hasin DS, Wall M, Witkiewitz K, Kranzler HR, Falk D, Litten R, et al. Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry. 2017;4(6):469–76.CrossRef Hasin DS, Wall M, Witkiewitz K, Kranzler HR, Falk D, Litten R, et al. Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry. 2017;4(6):469–76.CrossRef
25.
Zurück zum Zitat European Medicines Agency. Guideline on the development of medicinal products for the treatment of alcohol dependence. London: European Medicines Agency; 2010. European Medicines Agency. Guideline on the development of medicinal products for the treatment of alcohol dependence. London: European Medicines Agency; 2010.
26.
Zurück zum Zitat Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018;113(2):220–37.CrossRef Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018;113(2):220–37.CrossRef
27.
Zurück zum Zitat Bakhshi E, McArdle B, Mohammad K, Seifi B, Biglarian A. Let continuous outcome variables remain continuous. Comput Math Methods Med. 2012;2012:639124.CrossRef Bakhshi E, McArdle B, Mohammad K, Seifi B, Biglarian A. Let continuous outcome variables remain continuous. Comput Math Methods Med. 2012;2012:639124.CrossRef
28.
Zurück zum Zitat MacCallum RC, Zhang S, Preacher KJ, Rucker DD. On the practice of dichotomization of quantitative variables. Psychol Methods. 2002;7(1):19–40.CrossRef MacCallum RC, Zhang S, Preacher KJ, Rucker DD. On the practice of dichotomization of quantitative variables. Psychol Methods. 2002;7(1):19–40.CrossRef
29.
Zurück zum Zitat Yoo B. The impact of dichotomization in longitudinal data analysis: a simulation study. Pharm Stat. 2010;9(4):298–312.CrossRef Yoo B. The impact of dichotomization in longitudinal data analysis: a simulation study. Pharm Stat. 2010;9(4):298–312.CrossRef
30.
Zurück zum Zitat Witkiewitz K, Hallgren KA, Kranzler HR, Mann KF, Hasin DS, Falk DE, et al. Clinical validation of reduced alcohol consumption after treatment for alcohol dependence using the World Health Organization risk drinking levels. Alcohol Clin Exp Res. 2017;41(1):179–86.CrossRef Witkiewitz K, Hallgren KA, Kranzler HR, Mann KF, Hasin DS, Falk DE, et al. Clinical validation of reduced alcohol consumption after treatment for alcohol dependence using the World Health Organization risk drinking levels. Alcohol Clin Exp Res. 2017;41(1):179–86.CrossRef
31.
Zurück zum Zitat Tiffany ST, Friedman L, Greenfield SF, Hasin DS, Jackson R. Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction. 2012;107(4):709–18.CrossRef Tiffany ST, Friedman L, Greenfield SF, Hasin DS, Jackson R. Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction. 2012;107(4):709–18.CrossRef
32.
Zurück zum Zitat Carr AJ, Gibson B, Robinson PG. Measuring quality of life: is quality of life determined by expectations or experience? BMJ. 2001;322(7296):1240–3.CrossRef Carr AJ, Gibson B, Robinson PG. Measuring quality of life: is quality of life determined by expectations or experience? BMJ. 2001;322(7296):1240–3.CrossRef
33.
Zurück zum Zitat Donovan DM, Kivlahan DR, Doyle SR, Longabaugh R, Greenfield SF. Concurrent validity of the Alcohol Use Disorders Identification Test (AUDIT) and AUDIT zones in defining levels of severity among out-patients with alcohol dependence in the COMBINE study. Addiction. 2006;101(12):1696–704.CrossRef Donovan DM, Kivlahan DR, Doyle SR, Longabaugh R, Greenfield SF. Concurrent validity of the Alcohol Use Disorders Identification Test (AUDIT) and AUDIT zones in defining levels of severity among out-patients with alcohol dependence in the COMBINE study. Addiction. 2006;101(12):1696–704.CrossRef
34.
Zurück zum Zitat Becker SJ, Curry JF, Yang C. Longitudinal association between frequency of substance use and quality of life among adolescents receiving a brief outpatient intervention. Psychol Addict Behav. 2009;23(3):482–90.CrossRef Becker SJ, Curry JF, Yang C. Longitudinal association between frequency of substance use and quality of life among adolescents receiving a brief outpatient intervention. Psychol Addict Behav. 2009;23(3):482–90.CrossRef
35.
Zurück zum Zitat Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. Totowa: Human Press; 1992.CrossRef Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. Totowa: Human Press; 1992.CrossRef
36.
Zurück zum Zitat Miller WR. Form 90. A structured assessment interview for drinking and related behaviors: test manual. Bethesda: National Institute on Alcohol Abuse and Alcoholism; 1996. Miller WR. Form 90. A structured assessment interview for drinking and related behaviors: test manual. Bethesda: National Institute on Alcohol Abuse and Alcoholism; 1996.
37.
Zurück zum Zitat Shiffman S. Ecological momentary assessment (EMA) in studies of substance use. Psychol Assess. 2009;21(4):486–97.CrossRef Shiffman S. Ecological momentary assessment (EMA) in studies of substance use. Psychol Assess. 2009;21(4):486–97.CrossRef
38.
Zurück zum Zitat Simons JS, Wills TA, Emery NN, Marks RM. Quantifying alcohol consumption: self-report, transdermal assessment, and prediction of dependence symptoms. Addict Behav. 2015;50:205–12.CrossRef Simons JS, Wills TA, Emery NN, Marks RM. Quantifying alcohol consumption: self-report, transdermal assessment, and prediction of dependence symptoms. Addict Behav. 2015;50:205–12.CrossRef
39.
Zurück zum Zitat Maisto SA, Conigliaro JC, Gordon AJ, McGinnis KA, Justice AC. An experimental study of the agreement of self-administration and telephone administration of the timeline followback interview. J Stud Alcohol Drugs. 2008;69(3):468–71.CrossRef Maisto SA, Conigliaro JC, Gordon AJ, McGinnis KA, Justice AC. An experimental study of the agreement of self-administration and telephone administration of the timeline followback interview. J Stud Alcohol Drugs. 2008;69(3):468–71.CrossRef
40.
Zurück zum Zitat Pedersen ER, Grow J, Duncan S, Neighbors C, Larimer ME. Concurrent validity of an online version of the timeline followback assessment. Psychol Addict Behav. 2012;26(3):672–7.CrossRef Pedersen ER, Grow J, Duncan S, Neighbors C, Larimer ME. Concurrent validity of an online version of the timeline followback assessment. Psychol Addict Behav. 2012;26(3):672–7.CrossRef
41.
Zurück zum Zitat Del Boca FK, Darkes J. The validity of self-reports of alcohol consumption: state of the science and challenges for research. Addiction. 2003;98(Suppl 2):1–12.CrossRef Del Boca FK, Darkes J. The validity of self-reports of alcohol consumption: state of the science and challenges for research. Addiction. 2003;98(Suppl 2):1–12.CrossRef
42.
Zurück zum Zitat Finney JW, Moyer A, Swearingen CE. Outcome variables and their assessment in alcohol treatment studies: 1968–1998. Alcohol Clin Exp Res. 2003;27(10):1671–9.CrossRef Finney JW, Moyer A, Swearingen CE. Outcome variables and their assessment in alcohol treatment studies: 1968–1998. Alcohol Clin Exp Res. 2003;27(10):1671–9.CrossRef
43.
Zurück zum Zitat Andresen-Streichert H, Muller A, Glahn A, Skopp G, Sterneck M. Alcohol biomarkers in clinical and forensic contexts. Dtsch Arztebl Int. 2018;115(18):309–15.PubMedPubMedCentral Andresen-Streichert H, Muller A, Glahn A, Skopp G, Sterneck M. Alcohol biomarkers in clinical and forensic contexts. Dtsch Arztebl Int. 2018;115(18):309–15.PubMedPubMedCentral
44.
45.
Zurück zum Zitat Tavakoli HR, Hull M, Michael Okasinski L. Review of current clinical biomarkers for the detection of alcohol dependence. Innov Clin Neurosci. 2011;8(3):26–33.PubMedPubMedCentral Tavakoli HR, Hull M, Michael Okasinski L. Review of current clinical biomarkers for the detection of alcohol dependence. Innov Clin Neurosci. 2011;8(3):26–33.PubMedPubMedCentral
46.
Zurück zum Zitat Cabezas J, Lucey MR, Bataller R. Biomarkers for monitoring alcohol use. Clin Liver Dis. 2016;2:59–63.CrossRef Cabezas J, Lucey MR, Bataller R. Biomarkers for monitoring alcohol use. Clin Liver Dis. 2016;2:59–63.CrossRef
47.
Zurück zum Zitat Karns-Wright TE, Roache JD, Hill-Kapturczak N, Liang Y, Mullen J, Dougherty DM. Time delays in transdermal alcohol concentrations relative to breath alcohol concentrations. Alcohol Alcohol. 2017;52(1):35–41.CrossRef Karns-Wright TE, Roache JD, Hill-Kapturczak N, Liang Y, Mullen J, Dougherty DM. Time delays in transdermal alcohol concentrations relative to breath alcohol concentrations. Alcohol Alcohol. 2017;52(1):35–41.CrossRef
48.
Zurück zum Zitat Swift R. Transdermal alcohol measurement for estimation of blood alcohol concentration. Alcohol Clin Exp Res. 2000;24(4):422–3.CrossRef Swift R. Transdermal alcohol measurement for estimation of blood alcohol concentration. Alcohol Clin Exp Res. 2000;24(4):422–3.CrossRef
49.
Zurück zum Zitat Voas RB, DuPont RL, Talpins SK, Shea CL. Towards a national model for managing impaired driving offenders. Addiction. 2011;106(7):1221–7.CrossRef Voas RB, DuPont RL, Talpins SK, Shea CL. Towards a national model for managing impaired driving offenders. Addiction. 2011;106(7):1221–7.CrossRef
50.
Zurück zum Zitat Dougherty DM, Hill-Kapturczak N, Liang Y, Karns TE, Cates SE, Lake SL, et al. Use of continuous transdermal alcohol monitoring during a contingency management procedure to reduce excessive alcohol use. Drug Alcohol Depend. 2014;142:301–6.CrossRef Dougherty DM, Hill-Kapturczak N, Liang Y, Karns TE, Cates SE, Lake SL, et al. Use of continuous transdermal alcohol monitoring during a contingency management procedure to reduce excessive alcohol use. Drug Alcohol Depend. 2014;142:301–6.CrossRef
52.
Zurück zum Zitat Koffarnus MN, Bickel WK, Kablinger AS. Remote alcohol monitoring to facilitate incentive-based treatment for alcohol use disorder: a randomized trial. Alcohol Clin Exp Res. 2018;42(12):2423–31.CrossRef Koffarnus MN, Bickel WK, Kablinger AS. Remote alcohol monitoring to facilitate incentive-based treatment for alcohol use disorder: a randomized trial. Alcohol Clin Exp Res. 2018;42(12):2423–31.CrossRef
53.
Zurück zum Zitat Deci EL, Koestner R, Ryan RM. A meta-analytic review of experiments examining the effects of extrinsic rewards on intrinsic motivation. Psychol Bull. 1999;125(6):627–68 (discussion 92–700).CrossRef Deci EL, Koestner R, Ryan RM. A meta-analytic review of experiments examining the effects of extrinsic rewards on intrinsic motivation. Psychol Bull. 1999;125(6):627–68 (discussion 92–700).CrossRef
54.
Zurück zum Zitat Kwako LE, Momenan R, Litten RZ, Koob GF, Goldman D. Addictions neuroclinical assessment: a neuroscience-based framework for addictive disorders. Biol Psychiatry. 2016;80(3):179–89.CrossRef Kwako LE, Momenan R, Litten RZ, Koob GF, Goldman D. Addictions neuroclinical assessment: a neuroscience-based framework for addictive disorders. Biol Psychiatry. 2016;80(3):179–89.CrossRef
55.
Zurück zum Zitat Ray LA, Bujarski S, Roche DJO, Magill M. Overcoming the “valley of death” in medications development for alcohol use disorder. Alcohol Clin Exp Res. 2018;42(9):1612–22.CrossRef Ray LA, Bujarski S, Roche DJO, Magill M. Overcoming the “valley of death” in medications development for alcohol use disorder. Alcohol Clin Exp Res. 2018;42(9):1612–22.CrossRef
56.
Zurück zum Zitat Cook TD, Campbell DT. Quasi-experimentation: design and analysis issues for field settings. Chicago: Rand McNally; 1979. Cook TD, Campbell DT. Quasi-experimentation: design and analysis issues for field settings. Chicago: Rand McNally; 1979.
57.
Zurück zum Zitat Del Re AC, Maisel NC, Blodgett JC, Finney JW. Intention-to-treat analyses and missing data approaches in pharmacotherapy trials for alcohol use disorders. BMJ Open. 2013;3(11):e003464.CrossRef Del Re AC, Maisel NC, Blodgett JC, Finney JW. Intention-to-treat analyses and missing data approaches in pharmacotherapy trials for alcohol use disorders. BMJ Open. 2013;3(11):e003464.CrossRef
58.
Zurück zum Zitat Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21(3):287–92.CrossRef Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21(3):287–92.CrossRef
59.
Zurück zum Zitat O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881–7.CrossRef O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881–7.CrossRef
60.
Zurück zum Zitat Witkiewitz K, Falk DE, Kranzler HR, Litten RZ, Hallgren KA, O’Malley SS, et al. Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials. Alcohol Clin Exp Res. 2014;38(11):2826–34.CrossRef Witkiewitz K, Falk DE, Kranzler HR, Litten RZ, Hallgren KA, O’Malley SS, et al. Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials. Alcohol Clin Exp Res. 2014;38(11):2826–34.CrossRef
61.
Zurück zum Zitat Stout RL. Methodological and statistical considerations in measuring alcohol treatment effects. Alcohol Clin Exp Res. 2003;27(10):1686–91.CrossRef Stout RL. Methodological and statistical considerations in measuring alcohol treatment effects. Alcohol Clin Exp Res. 2003;27(10):1686–91.CrossRef
62.
Zurück zum Zitat Lehert P. Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol Alcohol Suppl. 1993;2:157–63.PubMed Lehert P. Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol Alcohol Suppl. 1993;2:157–63.PubMed
63.
Zurück zum Zitat Moncrieff J. A comparison of antidepressant trials using active and inert placebos. Int J Methods Psychiatr Res. 2003;12(3):117–27.CrossRef Moncrieff J. A comparison of antidepressant trials using active and inert placebos. Int J Methods Psychiatr Res. 2003;12(3):117–27.CrossRef
64.
Zurück zum Zitat Jensen JS, Bielefeldt AO, Hrobjartsson A. Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview. J Clin Epidemiol. 2017;87:35–46.CrossRef Jensen JS, Bielefeldt AO, Hrobjartsson A. Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview. J Clin Epidemiol. 2017;87:35–46.CrossRef
65.
Zurück zum Zitat Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;12:CD001867. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;12:CD001867.
66.
Zurück zum Zitat Litten RZ, Castle IJ, Falk D, Ryan M, Fertig J, Chen CM, et al. The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies. Alcohol Clin Exp Res. 2013;37(12):2128–37.CrossRef Litten RZ, Castle IJ, Falk D, Ryan M, Fertig J, Chen CM, et al. The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies. Alcohol Clin Exp Res. 2013;37(12):2128–37.CrossRef
67.
Zurück zum Zitat Khan A, Detke M, Khan SR, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003;191(4):211–8.PubMed Khan A, Detke M, Khan SR, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003;191(4):211–8.PubMed
68.
Zurück zum Zitat Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med. 2008;5(2):e45.CrossRef Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med. 2008;5(2):e45.CrossRef
69.
Zurück zum Zitat Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17.CrossRef Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17.CrossRef
70.
Zurück zum Zitat Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, et al. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36(8):1421–30.CrossRef Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, et al. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36(8):1421–30.CrossRef
71.
Zurück zum Zitat Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet. 2013;381(9861):91–2.CrossRef Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet. 2013;381(9861):91–2.CrossRef
72.
Zurück zum Zitat International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9. London: European Medicines Agency; 1998. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9. London: European Medicines Agency; 1998.
73.
Zurück zum Zitat Heffner JL, Tran GQ, Johnson CS, Barrett SW, Blom TJ, Thompson RD, et al. Combining motivational interviewing with compliance enhancement therapy (MI-CET): development and preliminary evaluation of a new, manual-guided psychosocial adjunct to alcohol-dependence pharmacotherapy. J Stud Alcohol Drugs. 2010;71(1):61–70.CrossRef Heffner JL, Tran GQ, Johnson CS, Barrett SW, Blom TJ, Thompson RD, et al. Combining motivational interviewing with compliance enhancement therapy (MI-CET): development and preliminary evaluation of a new, manual-guided psychosocial adjunct to alcohol-dependence pharmacotherapy. J Stud Alcohol Drugs. 2010;71(1):61–70.CrossRef
74.
Zurück zum Zitat Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet. 2002;359(9308):781–5.CrossRef Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet. 2002;359(9308):781–5.CrossRef
75.
Zurück zum Zitat Spieth PM, Kubasch AS, Penzlin AI, Illigens BM, Barlinn K, Siepmann T. Randomized controlled trials—a matter of design. Neuropsychiatr Dis Treat. 2016;12:1341–9.PubMedPubMedCentral Spieth PM, Kubasch AS, Penzlin AI, Illigens BM, Barlinn K, Siepmann T. Randomized controlled trials—a matter of design. Neuropsychiatr Dis Treat. 2016;12:1341–9.PubMedPubMedCentral
76.
Zurück zum Zitat Hallgren KA, Witkiewitz K. Missing data in alcohol clinical trials: a comparison of methods. Alcohol Clin Exp Res. 2013;37(12):2152–60.CrossRef Hallgren KA, Witkiewitz K. Missing data in alcohol clinical trials: a comparison of methods. Alcohol Clin Exp Res. 2013;37(12):2152–60.CrossRef
77.
Zurück zum Zitat Jackson D, White IR, Mason D, Sutton S. A general method for handling missing binary outcome data in randomized controlled trials. Addiction. 2014;109(12):1986–93.CrossRef Jackson D, White IR, Mason D, Sutton S. A general method for handling missing binary outcome data in randomized controlled trials. Addiction. 2014;109(12):1986–93.CrossRef
78.
Zurück zum Zitat Klemperer EM, Hughes JR, Naud S. Study characteristics influence the efficacy of substance abuse treatments: a meta-analysis of medications for alcohol use disorder. Drug Alcohol Depend. 2018;190:229–34.CrossRef Klemperer EM, Hughes JR, Naud S. Study characteristics influence the efficacy of substance abuse treatments: a meta-analysis of medications for alcohol use disorder. Drug Alcohol Depend. 2018;190:229–34.CrossRef
79.
Zurück zum Zitat Sobell MB, Sobell LC. Controlled drinking after 25 years: how important was the great debate? Addiction. 1995;90(9):1149–53 (discussion 57–77).CrossRef Sobell MB, Sobell LC. Controlled drinking after 25 years: how important was the great debate? Addiction. 1995;90(9):1149–53 (discussion 57–77).CrossRef
80.
Zurück zum Zitat Jones JD, Comer SD, Kranzler HR. The pharmacogenetics of alcohol use disorder. Alcohol Clin Exp Res. 2015;39(3):391–402.CrossRef Jones JD, Comer SD, Kranzler HR. The pharmacogenetics of alcohol use disorder. Alcohol Clin Exp Res. 2015;39(3):391–402.CrossRef
Metadaten
Titel
Outcome Assessment in Trials of Pharmacological Treatments for Alcohol Use Disorders: Fair and Strict Testing
verfasst von
Susanne Rösner
Michael Soyka
Publikationsdatum
01.07.2019
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 7/2019
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-019-00644-0

Weitere Artikel der Ausgabe 7/2019

CNS Drugs 7/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.